Image source: MolGen
News • Laboratory equipment
MolGen opens new UK office
DNA / RNA extraction technology, system, products and kits for human and animal diagnostics, agriculture, aquaculture, pharma and biotech solutions provider MolGen B.V., announces the recent opening of its UK office.
The new office is located at 6th Floor, South Quay Building, 189 Marsh Wall, London, E14 9SH. This expansion will enable the company to meet the rapidly increasing demand for cost-efficient, high quality diagnostic services in new markets. The new location will serve as a pivotal branch to provide professional laboratories based in London and the UK with access to MolGen’s extraction DNA / RNA portfolio across diagnostics, pharma and the biotech industry. The opening of this new office comes shortly after MolGen opened its US office in San Diego.
We see this new office as a way to further advance the testing and diagnostics industry and provide solutions as to how the world responds to disease and other life science conditionsNiels Kruize
“We have been fortunate to experience such rapid growth as a company. Our ability to scale quickly has been a great asset as we continue to strive to meet the growing demand for our innovations. We see this new office as a way to further advance the testing and diagnostics industry and provide solutions as to how the world responds to disease and other life science conditions,” said Niels Kruize, MolGen CCO.
MolGen UK will serve as the launch point for MolGen’s product MegaPrep – a bi-weekly, non-invasive monitoring PCR test that gives users the ability to analyse up to a million samples a day. Using more devices that can be customised to each lab, MegaPrep brings precision, speed and quality to the diagnostics workflow, resulting in accurate analysis at scale. As a pay-by-sample testing method it will help more parts of society, such as schools and business to remain open and combat disease, the company reports. With MegaPrep, MolGen UK strives to forge the future of testing capacity by extending the workflow with monitoring that involves low cost, high-frequency testing and delivers peace of mind to all.
Source: MolGen B.V.